A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Must have recovered from all side effects of their most recent systemic or local
treatment

- Adequate hematological, renal and liver function

For solid tumors only:

- Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer)
with a BRAF V600 mutation and that are resistant to standard therapy or for which
standard or curative therapy does not exist

- Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)

For multiple myeloma only:

- Confirmed diagnosis of multiple myeloma with a BRAF V600 mutation

- Must have received at least one prior systemic therapy for the treatment of multiple
myeloma

- Treated with local radiotherapy

- Must have relapsed and/or refractory multiple myeloma with measurable disease

Exclusion Criteria:

- Melanoma, papillary thyroid cancer or hematological malignancies (with the exception
of multiple myeloma)

- Uncontrolled concurrent malignancy

- Multiple myeloma: solitary bone or solitary extramedullary plasmacytoma as the only
evidence of plasma cell dyscrasia

- Active or untreated central nervous system (CNS) metastases

- History of or known carcinomatous meningitis

- Concurrent administration of any anti-cancer therapies other than those administered
in this study

- Other severe, acute, or chronic medical or psychiatric condition or laboratory
abnormality that would, in the investigator's opinion, contraindicate participation in
this study